A-796,260
Limited data
Limited data
Sparse data. Doses and effects may be unreliable or untested.
- 2 corroborating sources
- no dose data
- 2 corroborating sources
- no dose data
Summary
A-796,260 is a drug developed by Abbott Laboratories that acts as a potent and selective cannabinoid CB2 receptor agonist. Replacing the aromatic 3-benzoyl or 3-naphthoyl group found in most indole derived cannabinoids with the 3-tetramethylcyclopropylmethanone group, imparts significant selectivity for CB2, and A-796,260 was found to be a highly selective CB2 agonist with little affinity for CB1, having a CB2 Ki of 4.6 nM vs 945 nM at CB1. It has potent analgesic and anti-inflammatory actions in animal models, being especially effective in models of neuropathic pain, but without producing cannabis-like behavioral effects.
Effects
Helpful Links
Report an issue or suggest an edit
Spotted incorrect or dangerous information, have a correction, a new study, or a useful addition for A-796,260? Let us know. Reports are reviewed by moderators — this is not posted publicly.